Please login to the form below

Not currently logged in
Email:
Password:

ANVS401

This page shows the latest ANVS401 news and features for those working in and with pharma, biotech and healthcare.

Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s

Annovis Bio’s lead therapeutic shows ‘significant improvements’ in Alzheimer’s, Parkinson’s

The results come from a small phase 2a study evaluating ANVS401 in 14 AD patients and 14 PD patients. ... The ANVS401 treatment group also showed an improvement of 3.3 points (22%) compared to placebo at 25 days.

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Origins - The Patient Focused Specialists

Origins creates and delivers patient focused strategy, insights, data and solutions, which guides pharma and biotech companies to improve value...

Latest intelligence

Patient Clinical Trial & Communications Plan Review: A Customer Story
...
Working together to achieve better patient pathways
Digital tools can supercharge patient treatment and outcomes but the importance of the patient voice cannot be underestimated...
Design-thinking. Iterating for continuous improvement.
How design can lead improvement within Pharma...